SAFETY AND EFFICACY IN NVAF PATIENTS AFTER SUCCESSFUL TAVI IN ENVISAGE-TAVI AF TRIAL
Once-daily LIXIANA® was noninferior to well-managed VKA with the respect to the Net Adverse Clinical Events defined as a composite of all-cause death, myocardial infarction, ischemic stroke, systemic thromboembolic event, valve thrombosis, or major bleeding.1
PRIMARY EFFICACY OUTCOME: NET ADVERSE CLINICAL EVENTS (INTENTION-TO-TREAT POPULATION: N=1426)
a Patients taking LIXIANA® 60 mg as standard dose and those dose-reduced to 30 mg.
b Vitamin K antagonist. Median time-in-therapeutic range (TTR): 68.2%.
c Hazard ratio.
d Confidence interval.
Once-daily LIXIANA® had higher rate of major bleeding vs well-managed VKA, driven by more major gastrointestinal bleeding in the LIXIANA® group.1
PRIMARY SAFETY OUTCOME: MAJOR BLEEDING BY ISTH DEFINITION (INTENTION-TO-TREAT POPULATION: N=1426)
a Patients taking LIXIANA® 60 mg as standard dose and those dose-reduced to 30 mg.
b Vitamin K antagonist. Median time-in-therapeutic range (TTR): 68.2%.
c Hazard ratio.
d Confidence interval.
